TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04126369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness intervention
Description: The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psycho educative programme
Description: The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
Study: NCT02682888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: trait anxiety scale
Description: splitting subjects into 2 groups according to scores of the trait anxiety scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: trait anxiety scale
Description: splitting subjects into 2 groups according to scores of the trait anxiety scale

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin
Study: NCT04349371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
Study: NCT00760305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pro self pain control programme
Description: A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
Study: NCT01855503

Intervention type: PROCEDURE
Intervention: Core Biopsy
Study: NCT02787174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Medication Adherence Education
Study: NCT03485885

Intervention type: DIETARY_SUPPLEMENT
Intervention: Standardized maqui berry extract enriched in anthocyanins
Description: Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
Study: NCT03731455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WISE Cortical Strip
Description: The WISE Cortical Strip is a medical device composed by a strip and by a cable.
Study: NCT01707446

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)
Description: In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: An alarm threshold at 75% of the baseline rSO2 value
Description: If the threshold of \< 75% from baseline is reached for \> 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
Study: NCT03138382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Nerve Stimulator
Description: Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Nerve Stimulator
Description: Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulator
Description: Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulator
Description: Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
Study: NCT02423954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan + capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study: NCT02423954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study: NCT03016702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stress tests during functional MRI
Description: Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
Study: NCT03486496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Patients will be treated with gefitinib, 250 mg p.o., daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Patients will be treated with Berberine, 50 mg p.o., tid
Study: NCT03563443

Intervention type: DIAGNOSTIC_TEST
Intervention: Genomic Imprinting Testing
Description: The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)

Intervention type: DIAGNOSTIC_TEST
Intervention: Genomic Imprinting Testing
Description: The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
Study: NCT03369496

Intervention type: OTHER
Intervention: Social capital; Neighborhood environment
Description: Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
Study: NCT00935805

Intervention type: DRUG
Intervention: Metformin
Description: 850 mg TID

Intervention type: DRUG
Intervention: Glybenclamide
Description: 10 mg BID

Intervention type: DRUG
Intervention: NPH insulin
Description: Variable SC dose

Intervention type: DRUG
Intervention: Hydrochlorothiazide
Description: 25 mg QD introduced as initial therapy for hypertension

Intervention type: DRUG
Intervention: Propranolol
Description: 40 mg BID

Intervention type: DRUG
Intervention: Captopril
Description: 50 mg TID

Intervention type: DRUG
Intervention: Amlodipine
Description: 10 mg QD
Study: NCT03690349

Intervention type: OTHER
Intervention: Skin test
Description: Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens

Intervention type: OTHER
Intervention: Skin test
Description: Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
Study: NCT00000380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHRH

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GHRH
Study: NCT03806491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field. Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Study therapists will review a one-page handout on sleep hygiene with all participants. This is the only intervention that participants assigned to the sleep hygiene condition will receive. This is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorder Treatment as Usual
Description: CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Use Disorder Treatment as Usual
Description: CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
Study: NCT02837913

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VitaHeat underbody heating mattress
Description: Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaHeat underbody heating mattress
Description: Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
Study: NCT02682888

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration of placebo
Study: NCT03900013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fibrin combined with DFDBA
Description: The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Freeze Dried Bone Allograft
Description: Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
Study: NCT01532908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBL-HCV1
Description: 50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBL-HCV1
Description: 50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
Study: NCT01657032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smectite
Description: Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
Study: NCT03555279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm
Description: HIV Prevention Behavioral Health Intervention delivered by Probation Staff
Study: NCT01657032

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
Study: NCT01657032

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus GG
Description: All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
Study: NCT03555279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm
Description: HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
Study: NCT01657032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Description: All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
Study: NCT01333761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiox FDS
Description: The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
Study: NCT01710228

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: 192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
Study: NCT04420481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03668782

Intervention type: PROCEDURE
Intervention: Umbilical cord milking
Description: The babies were held at the level of the placenta, while the umbilical cord was milked or cut and clamped.
Study: NCT00978445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vMetrics protocol
Description: use vmetrics protocol and device or use standard in clinic monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vMetrics protocol
Description: use vmetrics protocol and device or use standard in clinic monitoring
Study: NCT05106660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory Laparoscopic Sleeve Gastrectomy
Description: Same-day discharge
Study: NCT00189280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: cream 5%, 5 days out of seven, for 6 weeks
Study: NCT05106660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laparoscopic Sleeve Gastrectomy
Description: Next-day discharge
Study: NCT00734422

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
Study: NCT02559817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide Dose B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide Dose C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide Approved Adult Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study: NCT03921281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scalp acupuncture treatment
Description: The parameters for scalp acupuncture are set as follows:~1. Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~2. Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~3. Treatment course: three times a week, 12 weeks in total.

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation Treatment
Description: The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
Study: NCT01018043

Intervention type: OTHER
Intervention: Adult Cancer Patients
Description: Tracking anemia management in Adult Cancer Patients
Study: NCT00890474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion of the BL67 acupoint
Description: Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
Study: NCT04558086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
Study: NCT03921281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Treatment
Description: The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
Study: NCT03864172

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual intake + placebo fruit juice
Description: Participants will consume 200 mls of placebo fruit flavoured juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual intake+SCF fruit juice
Description: Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
Study: NCT04558086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photo book
Description: To develop the intervention strategies of hospitalized school-age children with IV placement, using Photo book to further examine the effectiveness of reducing IV pain and fear.
Study: NCT02314455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-xylose
Description: There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
Study: NCT01788020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, Rituximab, Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
Study: NCT03864172

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adequate calcium + placebo fruit juice
Description: Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
Study: NCT03894943

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: Patient receive a PET/CT scan of their cerebrum and lumbar spine prior to surgery, 4-6 weeks after surgery and 6 months after surgery
Study: NCT03864172

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adequate calcium+ SCF fruit juice
Description: Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
Study: NCT02284906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo-matching tablets
Study: NCT00003019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Nitric oxide synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Nitric oxide synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Nitric oxide synthase inhibitor
Study: NCT03894943

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Patients undergo a battery of quantitative sensory tests prior to surgery, 4-6 weeks after surgery and 6 months after surgery
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Nitric oxide synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Nitric oxide synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Nitric oxide synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Nitric oxide synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Mitotic inhibitor, cytotoxic
Study: NCT01532908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir (Part 1)
Description: Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (Part 2)
Description: One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
Study: NCT02783287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder for medication adherence
Description: Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder for exercise regimen
Description: Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.